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1. Introduction
1.1. Cerebral glucose metabolism
Increases and decreases of synaptic activity in the brain are accompanied by proportional
changes in capillary perfusion and local glucose consumption. These changes in glucose
consumption are the effect of changed activity or density of the afferent nerve terminals in that
region. Loss of neurons may result in decreased glucose consumption in distant brain regions
by deafferentiation, while also increased regional glucose consumption by increased activation
of afferent neurons can occur. The PET tracer [18F]fluorodeoxyglucose (FDG) allows the
measurement of glucose consumption. FDG is a glucose analog with physiological aspects
almost identical to glucose. It is transported from the blood to the brain by a carrier-mediated
diffusion mechanism. FDG and glucose are phosphorylated by hexokinase as the first step of
the glycolytic process. FDG differs from glucose in that a hydrogen atom replaced the hydroxyl
group at the second carbon atom of the molecule. Glucose is then phosphorylated to glucose-6-
PO4, and continues along the glycolytic pathway for energy production. However, FDG is
phosphorylated to FDG-6-PO4, which is not a substrate for further metabolism and trapped in
tissues. As glucose is the only source of energy for the brain it reflects the neuronal integrity
of underlying brain pathology. Since FDG is a competitive substrate with glucose for both
transport and phosphorylation, it is important for tracer uptake to avoid high blood glucose
levels during an FDG-PET scan in subjects with diabetes.
In neurodegenerative brain diseases, specific brain regions degenerate and specific patterns
of metabolic brain activity develop. This happens before clear structural changes can be
detected with imaging techniques.
Measurement of glucose consumption with FDG PET imaging thus allows us to identify
disease-specific cerebral metabolic brain patterns in several neurodegenerative brain diseases
at an early disease stage. Since the first FDG PET study in man in 1979 (Reivich, et al. 1979)
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regional differences in cerebral glucose metabolism have been reported in various neurode‐
generative brain diseases including parkinsonian syndromes.
2. Disease-specific metabolic brain patterns: Methods
Univariate methods like voxel-based statistical parametric mapping (SPM) analyses have been
used to identify group differences between patients with neurodegenerative brain diseases
and controls. (Eckert, et al. 2005, Juh, et al. 2004, Yong, et al. 2007).
At the University Medical Center Groningen, The Netherlands we have performed a retro‐
spective study (Teune, et al. 2010) selecting typical patients with 7 different neurodegenerative
brain diseases who had had a clinical FDG brain scan at a time point when their diagnosis was
not sure yet. These patients developed in the following years the mentioned typical disease
states. Images of each of the seven patient groups were separately compared to controls using
a two-sample t test. At those early scans, already typical differences between patient - and
control groups were found for each disease.
However, Scaled Subprofile modelling/principal component analysis (SSM/PCA), a multi‐
variate method, not only identifies group differences, but is also able to identify relationships
in relatively increased and decreased metabolic activity between different brain regions in
combined samples of patients and control scans (Eidelberg. 2009, Moeller, et al. 1987).
Covariance analysis techniques are considered appropriate methods to explore network
activity. In the SSM, a threshold of the whole-brain maximum can be applied to remove out-
of-brain voxels, followed by a log transformation. A threshold of 35% is used by the Eidelberg
research group resulting in a mask of mainly grey matter (Spetsieris and Eidelberg. 2010). After
removing between-subject and between-region averages, a principal component analysis
(PCA) can be applied. PCA transformes a set of correlated variables into a new set of orthogonal
uncorrelated variables that are called the principal components. Voxels participating in each
principal component (PC) may have either a positive or a negative loading. The loadings
express the covariance structure (i.e. the strength of the interaction) between the voxels that
participate in the PC. They are ordered in terms of the variability they represent. That is, the
first principal components represents for a single dimension (variable) the greatest amount of
variability in the original dataset. Each succeeding orthogonal component accounts for as
much of the remaining variability as possible. They can be very helpful in determining how
many of the components are really significant and how much the data can be reduced.
In most studies, the components that together describe at least 50% of the variance are used
for further analysis, but this is an arbitrary limit. To identify a covariance pattern that best
discriminates a patient group from a control group, each subject’s expression of the selected
principal components with the lowest AIC (Akaike information criterion) value (Akaike.
1974) are entered into a stepwise regression procedure. This regression results in a linear
combination of the PCs that best discriminated the two groups and is designated as the disease-
specific metabolic covariance pattern.
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Important for its use in clinical practice is that this metabolic covariance pattern can then be
applied to individual patients to test whether they express the pattern or not. Every voxel value
in a subject scan is multiplied by the corresponding voxel weight in the covariance pattern,
with a subsequent summation over the whole brain volume. The resulting subject score
captures to what extent a subject expresses the covariance pattern.
Figure 1. Typical cerebral metabolic patterns in neurodegenerative brain diseases. SPM (t) maps of decreased meta‐
bolic activity were overlaid on a T1 MR template thresholded at P< 0.001 with cluster cutoff of 20 voxels. Patient
groups are indicated on the vertical axis and on the horizontal axis, seven transversal slices through the brain are
shown. PD = Parkinson’s disease: decreased metabolic activity in the contralateral to the most affected body side pari‐
eto-occipital and frontal regions; MSA = multiple system atrophy: decreased metabolic activity in bilateral putamen
and cerebellum; PSP = progressive supranuclear palsy: decreased metabolic activity in the prefrontal cortex, caudate
nucleus, thalamus and mesencephalon; CBD = corticobasal degeneration: decreased metabolic activity in the contrala‐
teral to the most affected body side cortical regions; DLB = dementia with Lewy bodies: decreased metabolic activity
in the occipital and parieto-temporal regions. AD = Alzheimer’s Disease: decreased metabolic activity in the angular
gyrus and other parieto-temporal regions including precuneus extending to the posterior- and middle cingulate gy‐
rus. FTD = frontotemporal dementia: decreased metabolic activity in the superior and inferior frontal gyrus, anterior
cingulate gyrus, SMA, sensorimotor area and middle temporal gyrus. Adapted from: Teune et al. (2010) Typical cere‐
bral metabolic patterns in neurodegenerative brain diseases. Movement Disorders. 2010;25:2395-404.
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3. Disease-specific metabolic brain patterns in patients with parkinsonism
3.1. Parkinson’s disease
Parkinson’s disease (PD) is characterized by bradykinesia, rigidity, sometimes rest tremor and
postural instability. A disturbed α-synuclein protein forming so-called Lewy bodies seems to
play a causal role, which was a reason to designate PD as a α-synucleinopathy. The main
pathophysiological changes result from degeneration of catecholaminergic, especially
dopaminergic cells in brainstem regions.
A characteristic metabolic covariance pattern has been identified in PD patients (PD-related
pattern, PDRP) showing regionally relatively increased metabolism in the globus pallidus and
putamen, thalamus, pons and cerebellum and relatively decreased metabolism in the lateral
frontal, premotor and parietal association areas (Ma, et al. 2007) Network expression in PD
patients also increases linearly with disease progression(Huang, et al. 2007b). Tang et al. tried
to study network changes in the PD-related motor pattern before symptom onset by studying
15 hemiparkinsonian patients and focusing mainly on the “presymptomatic” hemisphere.
They conclude that abnormal PDRP activity antecedes the appearance of motor signs by
approximately 2 years (Tang, et al. 2010a). However, this needs to be proven in future research
in true presymptomatic patients.
3.2. Parkinson’s disease and metabolic brain patterns related to specific symptoms
In addition to motor symptoms, cognitive dysfunction is also common in PD, especially
executive and visuospatial dysfunction. FDG-PET studies have been performed to study these
specific symptoms and their relations with neural network pathophysiology. The Eidelberg
research group has shown PD subclassifications related to specific symptoms. Network
analysis with the SSM/PCA approach detected a significant covariance pattern in non-
demented PD patients that correlated with memory and executive functioning tasks. The
expression of this PD-related cognitive pattern (PDCP) in individual patients correlated with
severity of cognitive dysfunction(Huang, et al. 2007a).
Alterations in neuropsychological test results in advanced PD were found to correlate with
decreases in glucose metabolism in the dorsolateral prefrontal cortex (DLPFC), lateral
orbitofrontal cortex (LOFC) ventral and dorsal cingulum (v/dACC) and in Broca area (Kalbe,
et al. 2009). In the study of Kalbe et al, PD patients with deep brain stimulation in the subtha‐
lamic nucleus (STN-DBS) showed cognitive decline that correlated with decrease in glucose
metabolism in these areas. In another study in STN-DBS treated patients, STN DBS was found
to activate glucose metabolism in the frontal limbic and associative territory (Hilker, et al.
2004). Interestingly, cortical areas that show hypometabolism in patients with depression
(Mayberg HS. 1994) are similar to the regions that show restored glucose metabolism after STN
DBS. This finding agrees with the clinical observation that PD-related depression tends to
improve after STN DBS.
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Mure et al. identified a spatial covariance pattern associated with Parkinson tremor which was
characterized by covarying increases in the cerebellum/dentate nucleus and primary cortex
and to a minor degree in the caudate/putamen (Mure, et al. 2011).
Hallucinations in PD have been related to relative frontal hypermetabolism compared to PD
patients without hallucinations(Nagano-Saito, et al. 2004). However, another study showed
hypometabolism in occipitotemporoparietal regions in PD patients with hallucinations,
sparing the occipital pole, while no significant increase in regional glucose metabolism was
detected (Boecker, et al. 2007). Interestingly, in patients with dementia with Lewy bodies
(DLB), who also suffer from hallucinations, glucose metabolism was also decreased in
occipitoparietal regions, however without sparing of the occipital pole (see DLB section).
3.3. Multiple system atrophy
Multiple system atrophy is a sporadic neurodegenerative brain disease which affects both men
and women and generally starts in the sixth decade of life. The main clinical features are
parkinsonism, autonomic failure, cerebellar ataxia, and pyramidal signs in any combination.
However, two major motor presentations can be distinguished. Parkinsonian features
predominate in 80% of patients (MSA-P subtype) and cerebellar ataxia is the main motor
feature in 20% of patients (MSA-C subtype) ((Gilman, et al. 2008, Wenning, et al. 1997)
In MSA-P the striatonigral system is the main site of pathology but less severe degeneration
can be widespread and normally includes the olivopontocerebellar system. In MSA-C
pathological changes are mainly seen in the olivopontocerebellar system and involvement of
striatum and substantia nigra are less severe (Wenning, et al. 1997). The discovery of glial
cytoplasmic inclusions in MSA brains highlighted the unique glial pathology as biological
hallmark of the disease. Their distribution selectively involves basal ganglia, supplementary
and primary motor cortex, the reticular formation and pontocerebellar system. Glial cytoplas‐
mic inclusions contain besides classical cytoskeletal antigens also α-synuclein, which is a
presynaptic protein present in Lewy Bodies, and this accumulation seems to play a central part
not only in MSA but also in other α-synucleinopathies such as PD and DLB.
Disease-related metabolic patterns were also present in MSA consisting of hypometabolism
in putamen and cerebellum in MSA (Eckert, et al. 2008). Poston et al. found that differences in
expression of the MSA-related pattern correlated with clinical disability (Poston, et al. 2012).
3.4. Progressive supranuclear palsy
The clinical picture of progressive supranuclear palsy (PSP) has been first described by Steele,
Richardson and Olszewski (Steele JC, Richardson J,Olszewski J. 1964) and is characterized by
progressive parkinsonism, early gait and balance impairment, vertical gaze palsy and more
profound frontal cognitive disturbances. PSP is one of several neurodegenerative diseases
characterised by accumulation of hyperphosphorylated tau (tauopathy), forming abnormal
filamentous inclusions in neurons and glia in the precentral and postcentral cortical areas but
also in the thalamus, subthalamic nucleus, red nucleus and substantia nigra. Other neurode‐
generative brain diseases which show disturbances in tau protein handling are corticobasal
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degeneration (CBD) and frontotemporal dementia (FTD) but there is also overlap in pathology
with Alzheimer’s disease (AD).
However the metabolic brain patterns in these tauopathies are quite different. The covariance
pattern of PSP consists of decreased metabolism in the prefrontal cortex, frontal eye fields,
caudate nuclei, medial thalamus and upper brainstem (Eckert, et al. 2008). Brain stem atrophy
and atrophy of the medial frontal cortical regions have also been reported in histopathological
studies (Hauw, et al. 1994).
3.5. Corticobasal degeneration
The most striking features of patients with corticobasal degeneration (CBD) include marked
asymmetrical parkinsonism and apraxia but also postural instability, limb dystonia, cortical
sensory loss, dementia and the alien limb phenomenon. CBD is one of the tauopathies and
clinical diagnosis is complicated by both the variability of presentation of true CBD and the
syndromes that look alike but are caused by other tauopathies with parkinsonism like PSP or
FTD (Josephs, et al. 2006). However with functional neuroimaging a clear distinction can be
made. In CBD a typical pattern of hypometabolism is seen in cortical regions contralateral to
the affected body side, including parieto-temporal regions, prefrontal cortex and motor cortex.
Furthermore, a decrease can be found in the contralateral caudate nucleus, putamen and
thalamus (Eckert, et al. 2005, Teune, et al. 2010). No covariance pattern has been described
using the SSM/PCA technique in CBD.
4. Disease-specific metabolic brain patterns in the differential diagnosis of
individual patients with parkinsonism
Interestingly, Tang and co-workers studied the potential role of FDG PET in the individual
diagnosis of 167 patients who had parkinsonian features but uncertain clinical diagnosis (Tang,
et al. 2010b) After FDG PET imaging, patients were assessed by blinded movement disorders
specialists for a mean of 2.6 years before a final clinical diagnosis was made (gold standard).
SSM/PCA analysis can quantify the expression of an obtained covariance pattern in each
subject which allows assessing the expression of a given pattern on a single case basis. Using
this automated image-based classification procedure and the previously defined disease
related covariance patterns in PD, MSA and PSP, individual patients were differentiated with
high specificity.
However, blinded, prospective imaging studies (ideally involving multiple centers, a larger
validation group, repeat imaging, and more extensive post-mortem confirmation) are needed
to establish the accuracy and precision of this pattern-based categorisation procedure. These
studies are currently undertaken.
For routine clinical practice, this knowledge of disease specific patterns of regional metabolic
activity in neurodegenerative brain diseases can be a valuable aid in the differential diagnosis
of individual patients, especially at an early disease stage.
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5. Disease-specific metabolic brain patterns in dementia
5.1. Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disease accounting for
50-60% of cases of dementia. AD is characterized by a severe decline in episodic memory
together with general cognitive symptoms such as impaired judgement, decision making and
orientation (McKhann, et al. 1984). A correct clinical diagnosis can be difficult, especially in
early disease stages or in patients with for example comorbid depression, high education or
young age (Bohnen, et al. 2012). FDG-PET imaging can be used to assist in the differential
diagnosis, because for different dementia syndromes, a separate pattern of hypometabolism
can be found. In Alzheimer’s disease (AD), decline of FDG uptake in posterior cingulate,
temporoparietal and prefrontal association cortex was related to dementia severity (Herholz,
et al. 2002). Foster et al used visual interpretation of an automated three-dimensional stereo‐
tactic surface projection technique of patients with AD and FTD. They showed that visual
interpretation of FDG-PET scans after training is more reliable and accurate in distinguishing
FTD from AD than clinical methods alone (Foster, et al. 2007).
Although multivariate analytical techniques might identify diagnostic patterns that are not
captured by univariate methods, they have rarely been used to study neural correlates of
Alzheimer’s Disease or cognitive impairment. Because cognitive processes are the result of
integrated activity in networks rather than activity of any one area in isolation, functional
connectivity can be better captured by multivariate methods. A study from Habeck et al.
examined the efficacy of multivariate and univariate analytical methods and concluded that
multivariate analysis might be more sensitive than univariate analysis for the diagnosis of early
Alzheimer’s disease (Habeck, et al. 2008).
Scarmeas et al. were the first to derive an AD related covariance pattern using H215O to measure
brain perfusion (Scarmeas, et al. 2004). It consisted of relatively increased perfusion in the
bilateral insula, lingual gyri and cuneus with bilaterally decreased flow in bilateral inferior
parietal lobule and cingulate in AD patients. However, using this PET tracer they found a
sensitivity of 76-94% and a specificity of 63-81% with considerable overlap in pattern expres‐
sion among AD patients and controls. Therefore they concluded that the derived H215O pattern
cannot be used as a sufficient diagnostic test in clinical settings. Specific FDG covariance
patterns to distinguish early AD-related cognitive decline using multivariate methods have
yet to be specified.
5.2. Frontotemporal dementia
Frontotemporal dementia (FTD) is one of the neurodegenerative diseases commonly mistaken
for AD. FTD patients do not have a true amnestic syndrome but can present with either gradual
and progressive changes in behaviour, or gradual and progressive language dysfunction.
Gross examination of the post-mortem brain from a patient with FTD usually reveals frontal
or temporal lobar atrophy or both, but the distribution or severity of brain atrophy are not
specific for a particular neurodegenerative brain disease. Jeong et al. and Diehl-Schmid et al.
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analysed FDG-PET scans of FTD patients on a voxel-by-voxel basis using Statistical Parametric
Mapping (SPM). They found hypometabolism depending on disease stage in the frontal lobe,
parietal and temporal cortices (Diehl-Schmid, et al. 2007, Jeong, et al. 2005).
5.3. Dementia with Lewy Bodies
The clinical overlap of dementia and parkinsonism is highlighted in Dementia with Lewy
Bodies (DLB). These patients show besides dementia extrapyramidal motor symptoms and
marked neuropsychiatric disturbances including visual hallucinations, depression, variability
in arousal and attention (McKeith. 2006). Consistent observation of a metabolic reduction in
the medial occipital cortex in DLB patients (Minoshima, et al. 2001, Teune, et al. 2010) using
FDG-PET imaging suggests the use of FDG-PET in the differential diagnosis of AD and DLB
and of PD and DLB. Minoshima et al. found that the presence of occipital hypometabolism
distinguished DLB from AD with 90% sensitivity and 80% specificity when using post-mortem
diagnosis as the gold standard diagnosis (Minoshima, et al. 2001).
6. Disease-specific metabolic brain patterns in hyperkinetic movement
disorders
6.1. Huntington’s disease
Huntington’s disease (HD) is characterized by progressive dementia and chorea, starting
around 30-40 years of age. HD is caused by a dominantly inherited CAG repeat expansion
mutation that generates lengthening of the protein huntingtin, with size-dependent neuro‐
toxicity. Several PET studies have shown hypometabolism in the caudate nucleus, both in
symptomatic and asymptomatic mutation carriers (Grafton, et al. 1992) (Antonini A., et al.
1996) In asymptomatic carriers, metabolic decreases were also significantly associated with
the CAG repeat number (Antonini A., et al. 1996). Furthermore, it was found that FDG uptake
in the caudate nucleus provided a predictive measure for time of onset of the disease, in
addition to the mutation size (Ciarmiello A., et al. 2012).
Another study applied network analysis of FDG-PET scans in presymptomatic mutation
carriers (Feigin, et al. 2001). They found a HD related metabolic covariance pattern (HDRP)
characterized by caudate and putamenal hypometabolism, but also including mediotemporal
reductions as well as relative increases in occipital regions. Disturbances of these striatotem‐
poral projections may underlie aspects of the psychiatric and cognitive abnormalities that
occur in the earliest stages of HD, before the onset of motor signs (Cummings JL. 1995).
6.2. Dystonia
Dystonia is a movement disorder characterized by involuntary, sustained muscle contractions
causing twisting movements and abnormal postures. The most common forms of primary
torsion dystonia (PTD) are DYT1 and DYT6, both caused by autosomal inherited mutations
with a reduced penetrance.
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Functional neuroimaging techniques have been applied in different dystonic disorders in‐
cluding primary generalized dystonia, mainly DYT1 and DYT6 and dopa-responsive dys‐
tonia,  as  well  as  focal  dystonic  syndromes  such  as  torticollis,  writer’s  cramp  and
blepharospasm.  A common finding is  abnormality  of  the  basal  ganglia,  cerebellum and
associated outflow pathways to sensorimotor cortex and other regions involved with mo‐
tor  performance.  However,  controversial  results  have  been found in  imaging dystonias,
partly attributed to methodological differences but also to the heterogeneity of the dysto‐
nias.  Using the SSM/PCA approach a reproducible pattern of abnormal regional glucose
utilization in  two independent  cohorts  of  DYT1 carriers  have been found (Eidelberg D.
1998)(Trost M., et al. 2002).
This torsion-dystonia related metabolic pattern is characterized by increases in the posterior
putamen/globus pallidus, cerebellum and SMA. Interestingly, also in clinically non-manifest‐
ing mutation carriers this pattern was found, suggesting a cerebral “vulnerability to develop
dystonia” network change. Also in manifesting and non-manifesting DYT 6 carriers abnormal
network activity has been identified. A difference between DYT1 and DYT6 metabolic patterns
can be seen in the putamen, where glucose metabolism is increased in DYT1 and decreased in
DYT6, possibly do to cell loss in DYT6. Furthermore, the cerebellum shows increased activity
in DYT1 and normal activity in DYT6 (Carbon M., et al. 2004).
The TDRP network is not expressed in patients with Dopa-responsive dystonia (DRD) (Trost
M., et al. 2002).
DRD is characterized by an early onset of dystonic symptoms and later appearance of
parkinsonian symptoms. A defining feature is a marked and sustained response to low doses
of levodopa, suggesting that the lesion may be functional in the presynaptic dopaminergic
system rather than anatomical. The DRD related metabolic pattern is characterized by relative
increases in the dorsal midbrain, cerebellar vermis,and SMA, assiocated with covarying
decreases in putamen, lateral premotor and motor cortical regions (Asanuma, et al. 2005b).
This DRD related pattern is not apparent in DYT 1 and 6 carriers supporting the hypothesis
that the pathophysiology of DRD differs from that of other forms of dystonia. They also found
that the Parkinson-related metabolic pattern is not apparent in DRD patients. Thus FDG-PET
can be useful to distinguish PD related dystonia from dopa-responsive dystonia with parkin‐
sonism (Asanuma, et al. 2005a).
6.3. Gilles de la Tourette
Tourette syndrome is characterized by the presence of chronic motor and vocal tics that
develop before the age of 18. Comorbid behavioural abnormalities are common in Tourette
syndrome, most notably obsessive-compulsive disorder and attention deficit/hyperactivity
disorder (Lebowitz, et al. 2012). The neurophysiology remains poorly understood with varying
and inconsistent neuropathological and neuroimaging findings, possibly due to the clinical
heterogeneity of the disorder. Pourfar et al. identified a Tourette syndrome related pattern
characterized by reduced metabolic activity of the striatum and orbitofrontal cortex associated
with relatively increased metabolic activity in the premotor cortex and cerebellum. A second
metabolic brain pattern was found in patients with Tourette syndrome and obsessive com‐
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pulsive disorder characterized by reduced activity in the anterior cingulate and dorsolateral
prefrontal cortex and relative increases in primary motor cortex and precuneus. Subject
expression correlated with symptom severity. These findings suggest that the different clinical
manifestations of the Tourette syndrome are associated with different abnormal brain
networks (Pourfar, et al. 2011).
7. Conclusion
FDG-PET imaging is increasingly available for routine clinical practice and has remained the
only available radiotracer to detect accurately and reliably the cerebral glucose metabolism.
As glucose is the only source of energy for the brain it reflects the energy needs of underlying
brain neuronal systems. The SSM/PCA method can identify relationships in relatively
increased and decreased metabolic activity between different brain regions in combined
samples of patients and controls. The expression of an obtained covariance pattern can be
quantified in an individual patient and this resulting subject score captures to what extent a
patient expresses the covariance patterns. The disease-related metabolic brain patterns can
therefore be a valuable aid in the early differential diagnosis of individual patients with
neurodegenerative brain diseases.
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